This paper explores emerging areas of pharmacogenomics that are becoming increasingly relevant to contemporary oncology pharmacy practice. The literature examined for this review was primarily drawn from recently approved therapeutics issued by the U.S. Food and Drug Administration and from newly incorporated treatment protocols within the National Comprehensive Cancer Network. The discussion highlights major pharmacogenomic themes, such as genomic variations that shape drug biotransformation, influence therapeutic response, and modify molecular targets; it also integrates significant clinical developments to offer a comprehensive perspective. The expanding repertoire of pharmacogenomic tools provides a robust platform for practice evolution and signals a transformative movement toward highly individualized treatment strategies.
